Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials

Results from previous randomised controlled trials (RCTs) investigating whether the addition of bevacizumab to neoadjuvant chemotherapy (NAC) could statistically significantly increase the pathological complete response (pCR) and to identify which subgroup would benefit most from such regimens have...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2015-12, Vol.10 (12), p.e0145442
Hauptverfasser:	Cao, Li, Yao, Guang-yu, Liu, Min-feng, Chen, Lu-jia, Hu, Xiao-lei, Ye, Chang-sheng
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetylcysteine Angiogenesis Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Bevacizumab - therapeutic use Biopsy Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Cancer Cancer therapies Care and treatment Chemotherapy Clinical trials Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Diagnosis Disease-Free Survival Dosage and administration ErbB-2 protein Female Hospitals Humans Immunotherapy Mastectomy Mastectomy, Segmental - methods Medical prognosis Medical research Meta-analysis Metastases Metastasis Monoclonal antibodies Neoadjuvant therapy Neoadjuvant Therapy - methods Neutropenia Oncology Patients Randomization Randomized Controlled Trials as Topic Receptor, ErbB-2 - genetics Risk factors Studies Surgery Systematic review Targeted cancer therapy Toxicity Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!